Transcriptional Signatures of the BCL2 Family in Acute Myeloid Leukaemia Treatment

We established BFSigs labeled as the BCL2, MCL1/BCL2, and BFL1/MCL1 signatures that identify key anti-apoptotic proteins. Unsupervised clustering based on BFSig information consistently classified AML patients into three robust subtypes across different AML cohorts, implying the existence of biological entities revealed by the BFSig approach. Lastly, we successfully confirmed the validity of BFSigs using NanoString technology. An AML NanoString dataset of 47 bone marrow samples was acquired from randomly chosen patients with AML diagnosed in Seoul National University Hospital (SNUH). We designed a custom NanoString nCounter expression panel with our 82 optimized genes and conducted an validation study using 47 AML samples.